380 related articles for article (PubMed ID: 26179066)
21. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
[TBL] [Abstract][Full Text] [Related]
22. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
[TBL] [Abstract][Full Text] [Related]
23. Oligopeptides impairing the Myc-Max heterodimerization inhibit lung cancer cell proliferation by reducing Myc transcriptional activity.
D'Agnano I; Valentini A; Gatti G; Chersi A; Felsani A
J Cell Physiol; 2007 Jan; 210(1):72-80. PubMed ID: 16998799
[TBL] [Abstract][Full Text] [Related]
24. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
25. Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
Koldehoff M; Zakrzewski JL; Beelen DW; Elmaagacli AH
Cancer Gene Ther; 2013 Jul; 20(7):421-7. PubMed ID: 23788109
[TBL] [Abstract][Full Text] [Related]
26. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph
Peter B; Eisenwort G; Sadovnik I; Bauer K; Willmann M; Rülicke T; Berger D; Stefanzl G; Greiner G; Hoermann G; Keller A; Wolf D; Čulen M; Winter GE; Hoffmann T; Schiefer AI; Sperr WR; Zuber J; Mayer J; Valent P
Am J Hematol; 2022 Sep; 97(9):1215-1225. PubMed ID: 35794848
[TBL] [Abstract][Full Text] [Related]
27. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.
Notari M; Neviani P; Santhanam R; Blaser BW; Chang JS; Galietta A; Willis AE; Roy DC; Caligiuri MA; Marcucci G; Perrotti D
Blood; 2006 Mar; 107(6):2507-16. PubMed ID: 16293596
[TBL] [Abstract][Full Text] [Related]
28. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein.
Li Y; Wang H; Tao K; Xiao Q; Huang Z; Zhong L; Cao W; Wen J; Feng W
Exp Cell Res; 2013 May; 319(8):1094-101. PubMed ID: 23428668
[TBL] [Abstract][Full Text] [Related]
29. Phosphorylation regulates Myc expression via prolonged activation of the mitogen-activated protein kinase pathway.
Wang Z; Ge L; Wang M; Carr BI
J Cell Physiol; 2006 Jul; 208(1):133-40. PubMed ID: 16596619
[TBL] [Abstract][Full Text] [Related]
30. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
[TBL] [Abstract][Full Text] [Related]
31. Down-regulation of Thanatos-associated protein 11 by BCR-ABL promotes CML cell proliferation through c-Myc expression.
Nakamura S; Yokota D; Tan L; Nagata Y; Takemura T; Hirano I; Shigeno K; Shibata K; Fujisawa S; Ohnishi K
Int J Cancer; 2012 Mar; 130(5):1046-59. PubMed ID: 21400515
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional regulation of survivin by c-Myc in BCR/ABL-transformed cells: implications in anti-leukaemic strategy.
Fang ZH; Dong CL; Chen Z; Zhou B; Liu N; Lan HF; Liang L; Liao WB; Zhang L; Han ZC
J Cell Mol Med; 2009 Aug; 13(8B):2039-2052. PubMed ID: 19602047
[TBL] [Abstract][Full Text] [Related]
33. Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia.
Gupta M; Milani L; Hermansson M; Simonsson B; Markevärn B; Syvänen AC; Barbany G
Biochem Biophys Res Commun; 2008 Feb; 366(3):848-51. PubMed ID: 18082628
[TBL] [Abstract][Full Text] [Related]
34. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
[TBL] [Abstract][Full Text] [Related]
35. The proto-oncogene expression varies over the course of chronic myeloid leukemia.
Vidović A; Janković G; Colović M; Tomin D; Perunicić M; Bila J; Marković O; Bosković D
Hematology; 2008 Feb; 13(1):34-40. PubMed ID: 18534064
[TBL] [Abstract][Full Text] [Related]
36. BMI-1 expression is enhanced through transcriptional and posttranscriptional regulation during the progression of chronic myeloid leukemia.
Bhattacharyya J; Mihara K; Yasunaga S; Tanaka H; Hoshi M; Takihara Y; Kimura A
Ann Hematol; 2009 Apr; 88(4):333-40. PubMed ID: 18781299
[TBL] [Abstract][Full Text] [Related]
37. Molecular biology of bcr-abl1-positive chronic myeloid leukemia.
Quintás-Cardama A; Cortes J
Blood; 2009 Feb; 113(8):1619-30. PubMed ID: 18827185
[TBL] [Abstract][Full Text] [Related]
38. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
[TBL] [Abstract][Full Text] [Related]
39. Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.
Sindt A; Deau B; Brahim W; Staal A; Visanica S; Villarese P; Rault JP; Macintyre E; Delabesse E
Genes Chromosomes Cancer; 2006 Jun; 45(6):575-82. PubMed ID: 16518848
[TBL] [Abstract][Full Text] [Related]
40. c-Myc creates an activation loop by transcriptionally repressing its own functional inhibitor, hMad4, in young fibroblasts, a loop lost in replicatively senescent fibroblasts.
Marcotte R; Chen JM; Huard S; Wang E
J Cell Biochem; 2005 Dec; 96(5):1071-85. PubMed ID: 16167342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]